

## SEQUENCE LISTING

<110> Gerhard , Walter  
Otvos, Laszlo

<120> COMPOSITION AND METHOD FOR PREVENTING OR TREATING A VIRUS  
INFECTION

<130> WSTR-0017B

<150> US 60/441,374  
<151> 2003-01-16

<160> 10

<170> PatentIn version 3.1

<210> 1  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic multiple antigenic agent

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal amino group has attached R1 which is 0 to 2 amino  
acid residues, wherein said amino acid residue may be a Gly or Cys,  
or a nucleic acid sequence.

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Side chain amino group has attached R2 which is a B cell  
determinant, a T cell determinant, or a targeting molecule.

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Side chain amino group has attached R3 which is a B cell  
determinant, a T cell determinant, or a targeting molecule.

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)  
<223> "Xaa" represents 0 to 1 amino acid residue of Lys-R4, wherein R4  
is a B cell determinant, a T cell determinant, or a targeting molecule.

<220>  
<221> MISC\_FEATURE  
<222> (5)..(5)

<223> C-terminus has attached R5 group which is an amino acid, peptide, or nucleic acid sequence.

<400> 1

Lys Gly Lys Gly Xaa  
1 5

<210> 2

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Mannosylated residue

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Mannosylated serine residue attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Mannosylated serine residue attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (6)..(6)

<223> Mannosylated serine residue attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (8)..(8)

<223> S2 peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (10)..(10)

<223> S1 peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (12)..(12)

<223> M2e peptide attached to side chain amino group

<400> 2

Ser Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala  
1 5 10

<210> 3

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Serine attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> Serine attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> S2 peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> S1 peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (11)..(11)

<223> M2e peptide attached to side chain amino group

<400> 3

Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Lys Gly Ala  
1 5 10

<210> 4

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

```
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Serine residue attached to side chain

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> S2 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> S1 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> M2e peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> M2e peptide attached to side chain amino group

<400> 4

Ser Cys Gly Lys Gly Lys Gly Lys Gly Ala
1           5           10

<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic multiple antigenic agent

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Dimer created by disulfide linkage

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> S2 peptide attached to side chain amino group

<220>
<221> MISC_FEATURE
<222> (5)..(5)
```

<223> S1 peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> M2e peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (9)..(9)

<223> M2e peptide attached to side chain amino group

<400> 5

Cys Gly Lys Gly Lys Gly Lys Gly Lys Ala  
1 5 10

<210> 6

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<400> 6

Cys Gly Lys Gly Lys Gly Lys Ala  
1 5

<210> 7

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic multiple antigenic agent

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> M2e peptide attached to side chain amino group

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> M2e peptide attached to side chain amino group

<400> 7

Cys Gly Lys Gly Lys Gly Lys Ala  
1 5

<210> 8  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic S1 peptide

<400> 8

Ser Phe Glu Arg Phe Glu Ile Phe Pro Lys Glu  
1 5 10

<210> 9  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic S2 peptide

<400> 9

His Asn Thr Asn Gly Val Thr Ala Ala Ser Ser His Glu  
1 5 10

<210> 10  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic M2e peptide

<400> 10

Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly Cys  
1 5 10 15

Arg Ser Asn Asp Ser Ser Asp Pro  
20